Physician profile
Alan W Thomas
NPI 1548297468
$1,867.35
in general payments reported to CMS, 2019-2025
13 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $317 · 2021: $228 · 2022: $315 · 2023: $185 · 2024: $188 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.44 |
| Education | $123.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $370.25 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $349.71 | 2020-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $323.90 | 2021-2025 | Rybrevant, Carvykti, Tecvayli |
| Celgene Corporation | $210.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Karyopharm Therapeutics INC. | $128.18 | 2020-2021 | |
| Abbvie INC. | $99.99 | 2024 | |
| Genmab U.S., INC. | $88.33 | 2024 | Epkinly |
| Amgen INC. | $41.88 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.47 | 2020-2021 | |
| Glaxosmithkline, LLC. | $31.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.87 | 2023 | Sprycel |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.